Chief Physician, Doctoral Supervisor, Director of the Department of Nuclear Medicine
Affiliated HospitalRuijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
→
-Research areas : PSMA diagnosis and treatment integration, prostate cancer molecular imaging, and radioligand translational research.
- Cutting-edge technologies: ¹⁸F-PSMA PET/MR imaging system; ¹⁷⁷Lu-PSMA target screening and dose assessment.
- Areas of expertise: PSMA molecular imaging assessment for prostate cancer, ¹⁷⁷Lu-PSMA radioligand therapy for advanced prostate cancer, and radionuclide therapy for thyroid cancer.
- Academic Highlights: Contributing expert to the "Expert Consensus on the Clinical Application of ¹⁷⁷Lu-PSMA Radioligand Therapy for Prostate Cancer"; Vice Chairman of the Shanghai Nuclear Society; Pioneer in the field of PSMA imaging in China.
- Core Value: To build Ruijin's integrated PSMA diagnosis and treatment platform and establish a standardized process for screening patients with ¹⁸F-PSMA PET/MR.